And Novo’s Wegovy pill, which has been a bright spot for the company, fell just short of analyst estimates for the second quarter. Lilly credited the continued growth of tirzepatide, the world’s best-selling drug, which is marketed as Mounjaro for diabetes and Zepbound for obesity. Dive Insight:Novo’s Ozempic, sold as Wegovy for obesity, was the first in the GLP-1 class of drugs to become a household name. Meanwhile, Novo disappointed investors in the one area where it’s shown an edge in the obesity drug market, with its Wegovy pill. Lilly said its revenue should reach between $85 billion and $87 billion for the year, up from an estimate of $82 billion to $85 billion.